Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation

Danchenko, Natalya; Johnston, Karissa; Haeussler, Katrin; Whalen, John

doi:10.1080/13696998.2021.1957582

Cited by 6 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who experienced reduced disability were considered to have improved, whereas those who remained in the previous health state or experienced increased disability were considered to have worsened. The efficacy of aboBoNT-A treatment was derived from the NCT01313299 and NCT01313312 clinical trial data, using the randomized trial data from baseline through 12 weeks and the open-label extension data through 48 weeks. We assumed that 10% of patients in each health state discontinued treatment after the first year.…”

Section: Efficacy and Transition Probabilities 631 Upper Limb Spastic...mentioning

confidence: 99%

“…BoNT-A injections have been found to be effective in enhancing patient mobility and decreasing the likelihood of complications such as joint deformity, tendon shortening, deep vein thrombosis, and pressure ulcers. The evidence shows that aboBoNT-A may produce a more robust response in pediatric patients with upper limb spasticity [ 12 ], as well as in adult patients with spasticity in their upper [ 13 ] or lower limbs [ 4 ], resulting in statistically significant reductions in muscle tone and overall improvement in patient function. BoNT-A offers a sustained alleviation of symptoms, resulting in extended intervals of enhanced mobility, reduced symptom-related anxieties, and heightened self-assurance for patients [ 11 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

Nomikos,

Eleftheriou,

Athanasakis

2023

Toxins

View full text Add to dashboard Cite

This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A). Clinical studies were utilized to extract data on drug efficacy and patients’ utility, while cost data were collected from Greek sources. The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC. Additionally, introducing aboBoNT-A into the Greek healthcare system resulted in cost savings in pharmaceutical spending over a 5-year period. The findings suggest that incorporating aboBoNT-A into the Greek healthcare system could improve patient access to treatment and healthcare resource efficiency, as it is a more economical option compared to onaBoNT-A.

show abstract

Section: Efficacy and Transition Probabilities 631 Upper Limb Spastic...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

Nomikos,

Eleftheriou,

Athanasakis

2023

Toxins

View full text Add to dashboard Cite

show abstract

“…A recent longitudinal, real-world study including 953 patients showed that aboBoNT-A treatment for upper LS is associated with longer injection intervals than other BoNT-A products [ 9 ]. Additionally, results from previous pharmacoeconomic studies in patients with LS [ 15 , 16 , 17 ] or cervical dystonia [ 18 ] show that aboBoNT-A treatment resulted in better QoL than onaBoNT-A treatment [ 16 , 17 ], and that it had a favorable cost profile compared with onaBoNT-A treatment, with the potential for cost savings without a reduction in clinical effectiveness [ 15 , 16 , 17 , 18 ]. This may support a switch from onaBoNT-A to aboBoNT-A in some cases to deliver more efficient management of spasticity in the UK [ 3 , 17 , 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity

Bezzina,

Degtiar,

Danchenko

et al. 2023

Toxins

View full text Add to dashboard Cite

Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015–2017) or aboBoNT-A (Cohort 2; 2017–2019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs. Adverse events were recorded for Cohort 2. Cohort 1 included 60 patients (mean [standard deviation] dose, 206.0 [98.8] U); Cohort 2 included 54 patients (753.7 [457.3] U). Mean (95% confidence interval) GAS-T scores for Cohorts 1 and 2 were 43.1 (39.3–46.9) and 47.8 (43.7–51.9) at Week 6, and 43.2 and 44.3 at Week 12, respectively. In both cohorts most patients were satisfied with treatment. At Week 12, QoL had not changed in Cohort 1 but had improved in Cohort 2 (EQ-5D VAS, −5). Mean estimated per-patient costs (in 2021) for Cohorts 1 and 2 were £315.56 and £249.25, respectively, at Week 6, and £343.20 and £273.21, respectively, at Week 12. Fifteen non–treatment-related serious adverse events and two deaths were recorded. These data may warrant a larger prospective study powered to compare outcomes of aboBoNT-A and onaBoNT-A.

show abstract

“…ABO has been widely used to treat cervical dystonia, limb spasticity, and other neuromuscular disorders, and has shown good safety and efficacy. [7][8][9] In recent years, ABO has also been used to treat glabellar lines and other facial wrinkles, and has achieved satisfactory results. [10][11][12] ABO can act directly on the glabellar muscles by injection, making them relax and smoothing glabellar lines, while maintaining the naturalness of facial expressions.…”

mentioning

confidence: 99%

Efficacy and Safety of AbobotulinumtoxinA for Treatment of Moderate-to-Severe Glabellar Lines: A Meta-Analysis

Han,

Bai,

Kuang

2024

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: This meta-analysis aimed to evaluate the safety and efficacy of abobotulinumtoxinA (ABO) and ABO solution for injection (ASI) for treating moderate-to-severe glabellar lines. Methods: The EMBASE, PubMed, and web of science databases were systematically searched. Methodological quality was checked using the Cochrane Risk of Bias tool. We also performed statistical analyses using Stata software to examine the efficacy and safety of ABO. Results: Nine randomized controlled trials were included in the meta-analysis. The results showed that at maximum frown, the proportion of responders as measured by the investigator’s live assessment and subject’s self-assessment of moderate-to-severe glabellar lines were significantly higher in the ABO and ASI treatment groups than in the placebo group. In addition, from baseline to maximum frown, the ≥1-grade improvement rate in moderate-to-severe glabellar lines severity was also significantly higher in the ABO and ASI treatment groups than in the placebo group. No significant differences in adverse events were found between ABO, ASI and placebo groups, indicating that ABO and ASI have good safety. Conclusions: ABO and ASI are effective and safe options for the treatment of moderate-to-severe glabellar lines. More high-quality studies are needed to verify these conclusions.

show abstract

Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation

Abstract: Comparative efficacy, safety and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison and economic evaluation

Cited by 6 publications

References 59 publications

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity

Efficacy and Safety of AbobotulinumtoxinA for Treatment of Moderate-to-Severe Glabellar Lines: A Meta-Analysis

Contact Info

Product

Resources

About